A Novel Augmented Reality System (ARssist & ARport) for the Assistant Surgeon in Robotic Assisted Surgery:

November 19, 2026 updated by: Jeremy Yuen Chun TEOH, Chinese University of Hong Kong

A Novel Augmented Reality System (ARssist & ARport) for the Assistant Surgeon in Robotic Assisted Surgery: A Pilot Study

Robotic prostatectomy is a surgery for treating localized prostate cancer. The ARssist & ARport system is a novel augmented reality system designed for the assistant surgeon, allowing delivery of augmented reality information. This study aims at evaluating the safety and feasibility of the use of ARssist & ARport system in robotic prostatectomy.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This is a prospective study to evaluate the clinical feasibility and safety of the ARssist and ARport system during robotic surgery with Robotic surgical System. During the operation, the assistant surgeon will utilize the ARssist & ARport system to assist the chief surgeon. Subjects will receive standard post-operative care. The primary objective of this study is to demonstrate the safety and clinical feasibility of the ARssist and ARport system in helping the patient side surgeon perform laparoscopic tasks during robotic assisted urological surgeries, with primary endpoints being safety data and complications.

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Ho Ming Chiris WONG, MBChB

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Patient Inclusion Criteria

  1. Age >18 years
  2. Body mass index <35kg/m2
  3. Suitable for minimally invasive surgery
  4. Willingness to participate as demonstrated by giving informed consent
  5. Clinically diagnosed with urological conditions that are indicated for robotic assisted radical prostatectomy with or without lymph node dissection

Patient Exclusion Criteria

  1. Contraindication to general anaesthesia
  2. Severe concomitant illness that drastically shortens life expectancy or increases risk of therapeutic intervention
  3. Untreated active infection
  4. Uncorrectable coagulopathy
  5. Presence of another malignancy or distant metastasis
  6. Emergency surgery
  7. Vulnerable population (e.g. mentally incapacitated persons)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: ARssist & ARport System

The surgery will follow the same steps of a standard robotic assisted radical prostatectomy procedure, with the addition of the ARssist and/or ARport system used by the patient side surgeon.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of intervention-related surgical complication
Time Frame: On Day 30

All post-operative complications within 30 days. Complications will be classified based on the Clavien-Dindo classification of surgical complications

On Day 30

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Performance of the patient side surgeon
Time Frame: Perioperative

By Global Operative Assessment of Laparoscopic Skills( GOALS) checklist, a 5-item global rating scale scored on a 5-point scale, the higher mark reflect the better performance

Perioperative
Specific feedback on the use of the system by patient side surgeon
Time Frame: Perioperative

A customized questionnaire of 10 items on a 5-point Likert scale ; the items included are selected and adopted from the feedback questionnaire designed for a study on HoloLens use in ureteroscopic procedure; by a System Usability Scale; the NASA Task Load Index and the Simulator sickness questionnaire. The higher the marks reflect the better performance

Perioperative
Operative Time
Time Frame: Perioperative

The duration of operation

Perioperative
Blood Loss
Time Frame: Perioperative

The total amount of blood loss in the operation in ml

Perioperative
Hospital Stay
Time Frame: Perioperative

Duration of hospital stay in days

Perioperative

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Yuen Chun Jeremy TEOH, MD, Chinese University of Hong Kong

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2026

Primary Completion (Estimated)

June 30, 2029

Study Completion (Estimated)

December 31, 2029

Study Registration Dates

First Submitted

October 25, 2026

First Submitted That Met QC Criteria

November 19, 2026

First Posted (Actual)

November 20, 2026

Study Record Updates

Last Update Posted (Actual)

November 20, 2026

Last Update Submitted That Met QC Criteria

November 19, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe